scholarly journals Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases

2008 ◽  
Vol 35 (7) ◽  
pp. 1394-1395 ◽  
Author(s):  
Marnix G. E. H. Lam ◽  
Bernard A. Zonnenberg
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Multimodality Treatment ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

Cancer ◽  
2007 ◽  
Vol 109 (6) ◽  
pp. 1090-1096 ◽  
Author(s):  
William K. Oh ◽  
Kevin Proctor ◽  
Mari Nakabayashi ◽  
Carolyn Evan ◽  
Lauren K. Tormey ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Renal Impairment ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

MER-101–03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5161-5161
Author(s):  
C. McHugh ◽  
K. Madigan ◽  
A. Walsh ◽  
J. Fox ◽  
T. W. Leonard ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Phase Ii ◽  
Performance Status ◽  
Hormone Refractory Prostate Cancer ◽  
Open Label ◽  
Secondary Endpoints ◽  
Hormone Refractory

5161 Background: The primary objective of this study is to examine the pharmacodynamic effects of two different regimens of zoledronic acid, Orazol 20 mg tablets versus Zometa 4mg IV infusion once-monthly therapy on biomarkers in male bisphosphonate-naïve hormone-refractory prostate cancer patients. Methods: The study is an open-label, multi-center phase II clinical trial to compare oral Orazol 20 mg tablets weekly, to infusions of intravenous Zometa 4mg monthly, in males with hormone-refractory prostate cancer, bone metastases, and no prior bisphosphonate treatment. Patients were assigned into one of three cohorts. The three treatments administered were IV Zometa, 4 mg, 15 minute infusion, Day 0 and Day 28; Orazol po, 20 mg, Days 0, 7, 14, 21, 28, 35, 42, and 49; and Orazol po, 20 mg, Days 0, 1, 2, 3, 28, 35, 42, and 49. The study population consisted of men with hormone refractory prostate cancer as evidenced by history of rising PSA levels (last 2 of 3 PSA levels must be above nadir), who are bisphosphonate-naive, and have radiographically-confirmed bone metastases. Efficacy assessments: The primary endpoints are the assessment of response of four biomarkers, urinary NTX, serum CTX, serum bone specific alkaline phosphatase, and serum calcium on days -7, 0, 7, 14, 21, 28, 35, 42, 49, and 56. Secondary endpoints are assessments of performance and pain scores based on ECOG performance status, BPI, and analgesic use. Safety assessments include physical examinations, vital signs and body weight, hematology panel, urinalysis, and blood chemistry panel. Results: The results demonstrated a rapid decrease for all four biomarkers. This decrease was seen at seven days, and was sustained throughout the study. There were no statistically significant differences between any of the treatments in the primary and secondary endpoints. Conclusions: From the results of MER-101–03, Orazol weekly therapy appears to be as effective as Zometa, based on the biomarkers analyzed. Orazol offers a substantial improvement in therapy over IV infusion for patients, with efficacy that is at least comparable based on the results obtained here. No significant financial relationships to disclose.

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

2011 ◽  
Vol 17 (8) ◽  
pp. 621-643 ◽  
Author(s):  
Jipan Xie ◽  
Madhav Namjoshi ◽  
Eric Q. Wu ◽  
Kejal Parikh ◽  
Melissa Diener ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Economic Evaluation ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

scholarly journals Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases

2007 ◽  
Vol 35 (4) ◽  
pp. 756-765 ◽  
Author(s):  
Marnix G. E. H. Lam ◽  
Amel Dahmane ◽  
Wil H. M. Stevens ◽  
Peter P. van Rijk ◽  
John M. H. de Klerk ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Hormone Refractory Prostate Cancer ◽  
Combined Use ◽  
Hormone Refractory

scholarly journals A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

2006 ◽  
Vol 12 (5) ◽  
pp. 1556-1563 ◽  
Author(s):  
Primo N. Lara ◽  
Walter M. Stadler ◽  
Jeff Longmate ◽  
David I. Quinn ◽  
Jason Wexler ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Matrix Metalloproteinase ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Phase Ii Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Matrix Metalloproteinase Inhibitor ◽  
Randomized Phase Ii ◽  
The Matrix ◽  
Hormone Refractory

scholarly journals Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients

2004 ◽  
Vol 7 (4) ◽  
pp. 350-354 ◽  
Author(s):  
P Rodrigues ◽  
F Hering ◽  
J C Campagnari
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‘good prognosis’ metastatic hormone refractory prostate cancer patients

2001 ◽  
Vol 37 ◽  
pp. S218 ◽  
Author(s):  
L. Collette ◽  
S.D. Fossa ◽  
G.O.N. Oosterhof ◽  
W. Albrecht ◽  
G. van Andel ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Good Prognosis ◽  
Hormone Refractory Prostate Cancer ◽  
Eortc Qlq C30 ◽  
Hormone Refractory ◽  
Eortc Qlq
Sign in / Sign up

Export Citation Format

Share Document